Neuropathic pain therapeutics refers to a way to relieve and treat neuropathic pain through various drugs or treatments. Neuropathic pain is a chronic condition wherein pathological pain continues even after the cause of the pain is eliminated.

The global Neuropathic Pain Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Neuropathic Pain Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuropathic Pain Therapeutics.

Report Scope

The Neuropathic Pain Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neuropathic Pain Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Neuropathic Pain Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Neuropathic Pain Therapeutics Market Report

Report Metric	Details
Report Name	Neuropathic Pain Therapeutics Market
CAGR	5%
Segment by Type	Anticonvulsants Antidepressants NSAIDs Opioids Steroids Others
Segment by Application	Diabetic Neuropathy Chemotherapy-Induced Neuropathy Pain Postherpetic Neuralgia Spinal Cord Injury Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer, Novartis AG, AstraZeneca, GlaxoSmithKline, Eli Lilly and Company, Mallinckrodt Pharmaceuticals, Johnson & Johnson, Abbott, Endo Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited, Merck & Co
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Neuropathic Pain Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Neuropathic Pain Therapeutics Market report?

Ans: The main players in the Neuropathic Pain Therapeutics Market are Pfizer, Novartis AG, AstraZeneca, GlaxoSmithKline, Eli Lilly and Company, Mallinckrodt Pharmaceuticals, Johnson & Johnson, Abbott, Endo Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited, Merck & Co

What are the Application segmentation covered in the Neuropathic Pain Therapeutics Market report?

Ans: The Applications covered in the Neuropathic Pain Therapeutics Market report are Diabetic Neuropathy, Chemotherapy-Induced Neuropathy Pain, Postherpetic Neuralgia, Spinal Cord Injury, Others

What are the Type segmentation covered in the Neuropathic Pain Therapeutics Market report?

Ans: The Types covered in the Neuropathic Pain Therapeutics Market report are Anticonvulsants, Antidepressants, NSAIDs, Opioids, Steroids, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Neuropathic Pain Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Anticonvulsants

1.2.3 Antidepressants

1.2.4 NSAIDs

1.2.5 Opioids

1.2.6 Steroids

1.2.7 Others

1.3 Market by Application

1.3.1 Global Neuropathic Pain Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Diabetic Neuropathy

1.3.3 Chemotherapy-Induced Neuropathy Pain

1.3.4 Postherpetic Neuralgia

1.3.5 Spinal Cord Injury

1.3.6 Others

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Neuropathic Pain Therapeutics Market Perspective (2019-2030)

2.2 Neuropathic Pain Therapeutics Growth Trends by Region

2.2.1 Global Neuropathic Pain Therapeutics Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Neuropathic Pain Therapeutics Historic Market Size by Region (2019-2024)

2.2.3 Neuropathic Pain Therapeutics Forecasted Market Size by Region (2025-2030)

2.3 Neuropathic Pain Therapeutics Market Dynamics

2.3.1 Neuropathic Pain Therapeutics Industry Trends

2.3.2 Neuropathic Pain Therapeutics Market Drivers

2.3.3 Neuropathic Pain Therapeutics Market Challenges

2.3.4 Neuropathic Pain Therapeutics Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Neuropathic Pain Therapeutics Players by Revenue

3.1.1 Global Top Neuropathic Pain Therapeutics Players by Revenue (2019-2024)

3.1.2 Global Neuropathic Pain Therapeutics Revenue Market Share by Players (2019-2024)

3.2 Global Neuropathic Pain Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Neuropathic Pain Therapeutics Revenue

3.4 Global Neuropathic Pain Therapeutics Market Concentration Ratio

3.4.1 Global Neuropathic Pain Therapeutics Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Neuropathic Pain Therapeutics Revenue in 2023

3.5 Neuropathic Pain Therapeutics Key Players Head office and Area Served

3.6 Key Players Neuropathic Pain Therapeutics Product Solution and Service

3.7 Date of Enter into Neuropathic Pain Therapeutics Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Neuropathic Pain Therapeutics Breakdown Data by Type

4.1 Global Neuropathic Pain Therapeutics Historic Market Size by Type (2019-2024)

4.2 Global Neuropathic Pain Therapeutics Forecasted Market Size by Type (2025-2030)

5 Neuropathic Pain Therapeutics Breakdown Data by Application

5.1 Global Neuropathic Pain Therapeutics Historic Market Size by Application (2019-2024)

5.2 Global Neuropathic Pain Therapeutics Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Neuropathic Pain Therapeutics Market Size (2019-2030)

6.2 North America Neuropathic Pain Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Neuropathic Pain Therapeutics Market Size by Country (2019-2024)

6.4 North America Neuropathic Pain Therapeutics Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Neuropathic Pain Therapeutics Market Size (2019-2030)

7.2 Europe Neuropathic Pain Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Neuropathic Pain Therapeutics Market Size by Country (2019-2024)

7.4 Europe Neuropathic Pain Therapeutics Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Neuropathic Pain Therapeutics Market Size (2019-2030)

8.2 Asia-Pacific Neuropathic Pain Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2019-2024)

8.4 Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Neuropathic Pain Therapeutics Market Size (2019-2030)

9.2 Latin America Neuropathic Pain Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Neuropathic Pain Therapeutics Market Size by Country (2019-2024)

9.4 Latin America Neuropathic Pain Therapeutics Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Neuropathic Pain Therapeutics Market Size (2019-2030)

10.2 Middle East & Africa Neuropathic Pain Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2019-2024)

10.4 Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer

11.1.1 Pfizer Company Detail

11.1.2 Pfizer Business Overview

11.1.3 Pfizer Neuropathic Pain Therapeutics Introduction

11.1.4 Pfizer Revenue in Neuropathic Pain Therapeutics Business (2019-2024)

11.1.5 Pfizer Recent Development

11.2 Novartis AG

11.2.1 Novartis AG Company Detail

11.2.2 Novartis AG Business Overview

11.2.3 Novartis AG Neuropathic Pain Therapeutics Introduction

11.2.4 Novartis AG Revenue in Neuropathic Pain Therapeutics Business (2019-2024)

11.2.5 Novartis AG Recent Development

11.3 AstraZeneca

11.3.1 AstraZeneca Company Detail

11.3.2 AstraZeneca Business Overview

11.3.3 AstraZeneca Neuropathic Pain Therapeutics Introduction

11.3.4 AstraZeneca Revenue in Neuropathic Pain Therapeutics Business (2019-2024)

11.3.5 AstraZeneca Recent Development

11.4 GlaxoSmithKline

11.4.1 GlaxoSmithKline Company Detail

11.4.2 GlaxoSmithKline Business Overview

11.4.3 GlaxoSmithKline Neuropathic Pain Therapeutics Introduction

11.4.4 GlaxoSmithKline Revenue in Neuropathic Pain Therapeutics Business (2019-2024)

11.4.5 GlaxoSmithKline Recent Development

11.5 Eli Lilly and Company

11.5.1 Eli Lilly and Company Company Detail

11.5.2 Eli Lilly and Company Business Overview

11.5.3 Eli Lilly and Company Neuropathic Pain Therapeutics Introduction

11.5.4 Eli Lilly and Company Revenue in Neuropathic Pain Therapeutics Business (2019-2024)

11.5.5 Eli Lilly and Company Recent Development

11.6 Mallinckrodt Pharmaceuticals

11.6.1 Mallinckrodt Pharmaceuticals Company Detail

11.6.2 Mallinckrodt Pharmaceuticals Business Overview

11.6.3 Mallinckrodt Pharmaceuticals Neuropathic Pain Therapeutics Introduction

11.6.4 Mallinckrodt Pharmaceuticals Revenue in Neuropathic Pain Therapeutics Business (2019-2024)

11.6.5 Mallinckrodt Pharmaceuticals Recent Development

11.7 Johnson & Johnson

11.7.1 Johnson & Johnson Company Detail

11.7.2 Johnson & Johnson Business Overview

11.7.3 Johnson & Johnson Neuropathic Pain Therapeutics Introduction

11.7.4 Johnson & Johnson Revenue in Neuropathic Pain Therapeutics Business (2019-2024)

11.7.5 Johnson & Johnson Recent Development

11.8 Abbott

11.8.1 Abbott Company Detail

11.8.2 Abbott Business Overview

11.8.3 Abbott Neuropathic Pain Therapeutics Introduction

11.8.4 Abbott Revenue in Neuropathic Pain Therapeutics Business (2019-2024)

11.8.5 Abbott Recent Development

11.9 Endo Pharmaceuticals, Inc.

11.9.1 Endo Pharmaceuticals, Inc. Company Detail

11.9.2 Endo Pharmaceuticals, Inc. Business Overview

11.9.3 Endo Pharmaceuticals, Inc. Neuropathic Pain Therapeutics Introduction

11.9.4 Endo Pharmaceuticals, Inc. Revenue in Neuropathic Pain Therapeutics Business (2019-2024)

11.9.5 Endo Pharmaceuticals, Inc. Recent Development

11.10 Teva Pharmaceutical Industries Limited

11.10.1 Teva Pharmaceutical Industries Limited Company Detail

11.10.2 Teva Pharmaceutical Industries Limited Business Overview

11.10.3 Teva Pharmaceutical Industries Limited Neuropathic Pain Therapeutics Introduction

11.10.4 Teva Pharmaceutical Industries Limited Revenue in Neuropathic Pain Therapeutics Business (2019-2024)

11.10.5 Teva Pharmaceutical Industries Limited Recent Development

11.11 Merck & Co

11.11.1 Merck & Co Company Detail

11.11.2 Merck & Co Business Overview

11.11.3 Merck & Co Neuropathic Pain Therapeutics Introduction

11.11.4 Merck & Co Revenue in Neuropathic Pain Therapeutics Business (2019-2024)

11.11.5 Merck & Co Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Eli Lilly and Company

Mallinckrodt Pharmaceuticals

Johnson & Johnson

Abbott

Endo Pharmaceuticals Inc

Teva Pharmaceutical Industries Limited

Merck

List of Tables

Table 1. Global Neuropathic Pain Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Anticonvulsants

Table 3. Key Players of Antidepressants

Table 4. Key Players of NSAIDs

Table 5. Key Players of Opioids

Table 6. Key Players of Steroids

Table 7. Key Players of Others

Table 8. Global Neuropathic Pain Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Neuropathic Pain Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 10. Global Neuropathic Pain Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 11. Global Neuropathic Pain Therapeutics Market Share by Region (2019-2024)

Table 12. Global Neuropathic Pain Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 13. Global Neuropathic Pain Therapeutics Market Share by Region (2025-2030)

Table 14. Neuropathic Pain Therapeutics Market Trends

Table 15. Neuropathic Pain Therapeutics Market Drivers

Table 16. Neuropathic Pain Therapeutics Market Challenges

Table 17. Neuropathic Pain Therapeutics Market Restraints

Table 18. Global Neuropathic Pain Therapeutics Revenue by Players (2019-2024) & (US$ Million)

Table 19. Global Neuropathic Pain Therapeutics Market Share by Players (2019-2024)

Table 20. Global Top Neuropathic Pain Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuropathic Pain Therapeutics as of 2023)

Table 21. Ranking of Global Top Neuropathic Pain Therapeutics Companies by Revenue (US$ Million) in 2023

Table 22. Global 5 Largest Players Market Share by Neuropathic Pain Therapeutics Revenue (CR5 and HHI) & (2019-2024)

Table 23. Key Players Headquarters and Area Served

Table 24. Key Players Neuropathic Pain Therapeutics Product Solution and Service

Table 25. Date of Enter into Neuropathic Pain Therapeutics Market

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. Global Neuropathic Pain Therapeutics Market Size by Type (2019-2024) & (US$ Million)

Table 28. Global Neuropathic Pain Therapeutics Revenue Market Share by Type (2019-2024)

Table 29. Global Neuropathic Pain Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 30. Global Neuropathic Pain Therapeutics Revenue Market Share by Type (2025-2030)

Table 31. Global Neuropathic Pain Therapeutics Market Size by Application (2019-2024) & (US$ Million)

Table 32. Global Neuropathic Pain Therapeutics Revenue Market Share by Application (2019-2024)

Table 33. Global Neuropathic Pain Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 34. Global Neuropathic Pain Therapeutics Revenue Market Share by Application (2025-2030)

Table 35. North America Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 36. North America Neuropathic Pain Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 37. North America Neuropathic Pain Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 38. Europe Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 39. Europe Neuropathic Pain Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 40. Europe Neuropathic Pain Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 41. Asia-Pacific Neuropathic Pain Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 42. Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2019-2024) & (US$ Million)

Table 43. Asia-Pacific Neuropathic Pain Therapeutics Market Size by Region (2025-2030) & (US$ Million)

Table 44. Latin America Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 45. Latin America Neuropathic Pain Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 46. Latin America Neuropathic Pain Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 47. Middle East & Africa Neuropathic Pain Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 48. Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Neuropathic Pain Therapeutics Market Size by Country (2025-2030) & (US$ Million)

Table 50. Pfizer Company Detail

Table 51. Pfizer Business Overview

Table 52. Pfizer Neuropathic Pain Therapeutics Product

Table 53. Pfizer Revenue in Neuropathic Pain Therapeutics Business (2019-2024) & (US$ Million)

Table 54. Pfizer Recent Development

Table 55. Novartis AG Company Detail

Table 56. Novartis AG Business Overview

Table 57. Novartis AG Neuropathic Pain Therapeutics Product

Table 58. Novartis AG Revenue in Neuropathic Pain Therapeutics Business (2019-2024) & (US$ Million)

Table 59. Novartis AG Recent Development

Table 60. AstraZeneca Company Detail

Table 61. AstraZeneca Business Overview

Table 62. AstraZeneca Neuropathic Pain Therapeutics Product

Table 63. AstraZeneca Revenue in Neuropathic Pain Therapeutics Business (2019-2024) & (US$ Million)

Table 64. AstraZeneca Recent Development

Table 65. GlaxoSmithKline Company Detail

Table 66. GlaxoSmithKline Business Overview

Table 67. GlaxoSmithKline Neuropathic Pain Therapeutics Product

Table 68. GlaxoSmithKline Revenue in Neuropathic Pain Therapeutics Business (2019-2024) & (US$ Million)

Table 69. GlaxoSmithKline Recent Development

Table 70. Eli Lilly and Company Company Detail

Table 71. Eli Lilly and Company Business Overview

Table 72. Eli Lilly and Company Neuropathic Pain Therapeutics Product

Table 73. Eli Lilly and Company Revenue in Neuropathic Pain Therapeutics Business (2019-2024) & (US$ Million)

Table 74. Eli Lilly and Company Recent Development

Table 75. Mallinckrodt Pharmaceuticals Company Detail

Table 76. Mallinckrodt Pharmaceuticals Business Overview

Table 77. Mallinckrodt Pharmaceuticals Neuropathic Pain Therapeutics Product

Table 78. Mallinckrodt Pharmaceuticals Revenue in Neuropathic Pain Therapeutics Business (2019-2024) & (US$ Million)

Table 79. Mallinckrodt Pharmaceuticals Recent Development

Table 80. Johnson & Johnson Company Detail

Table 81. Johnson & Johnson Business Overview

Table 82. Johnson & Johnson Neuropathic Pain Therapeutics Product

Table 83. Johnson & Johnson Revenue in Neuropathic Pain Therapeutics Business (2019-2024) & (US$ Million)

Table 84. Johnson & Johnson Recent Development

Table 85. Abbott Company Detail

Table 86. Abbott Business Overview

Table 87. Abbott Neuropathic Pain Therapeutics Product

Table 88. Abbott Revenue in Neuropathic Pain Therapeutics Business (2019-2024) & (US$ Million)

Table 89. Abbott Recent Development

Table 90. Endo Pharmaceuticals, Inc. Company Detail

Table 91. Endo Pharmaceuticals, Inc. Business Overview

Table 92. Endo Pharmaceuticals, Inc. Neuropathic Pain Therapeutics Product

Table 93. Endo Pharmaceuticals, Inc. Revenue in Neuropathic Pain Therapeutics Business (2019-2024) & (US$ Million)

Table 94. Endo Pharmaceuticals, Inc. Recent Development

Table 95. Teva Pharmaceutical Industries Limited Company Detail

Table 96. Teva Pharmaceutical Industries Limited Business Overview

Table 97. Teva Pharmaceutical Industries Limited Neuropathic Pain Therapeutics Product

Table 98. Teva Pharmaceutical Industries Limited Revenue in Neuropathic Pain Therapeutics Business (2019-2024) & (US$ Million)

Table 99. Teva Pharmaceutical Industries Limited Recent Development

Table 100. Merck & Co Company Detail

Table 101. Merck & Co Business Overview

Table 102. Merck & Co Neuropathic Pain Therapeutics Product

Table 103. Merck & Co Revenue in Neuropathic Pain Therapeutics Business (2019-2024) & (US$ Million)

Table 104. Merck & Co Recent Development

Table 105. Research Programs/Design for This Report

Table 106. Key Data Information from Secondary Sources

Table 107. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Neuropathic Pain Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Neuropathic Pain Therapeutics Market Share by Type: 2023 VS 2030

Figure 3. Anticonvulsants Features

Figure 4. Antidepressants Features

Figure 5. NSAIDs Features

Figure 6. Opioids Features

Figure 7. Steroids Features

Figure 8. Others Features

Figure 9. Global Neuropathic Pain Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 10. Global Neuropathic Pain Therapeutics Market Share by Application: 2023 VS 2030

Figure 11. Diabetic Neuropathy Case Studies

Figure 12. Chemotherapy-Induced Neuropathy Pain Case Studies

Figure 13. Postherpetic Neuralgia Case Studies

Figure 14. Spinal Cord Injury Case Studies

Figure 15. Others Case Studies

Figure 16. Neuropathic Pain Therapeutics Report Years Considered

Figure 17. Global Neuropathic Pain Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 18. Global Neuropathic Pain Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 19. Global Neuropathic Pain Therapeutics Market Share by Region: 2023 VS 2030

Figure 20. Global Neuropathic Pain Therapeutics Market Share by Players in 2023

Figure 21. Global Top Neuropathic Pain Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuropathic Pain Therapeutics as of 2023)

Figure 22. The Top 10 and 5 Players Market Share by Neuropathic Pain Therapeutics Revenue in 2023

Figure 23. North America Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. North America Neuropathic Pain Therapeutics Market Share by Country (2019-2030)

Figure 25. United States Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. Canada Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Europe Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Europe Neuropathic Pain Therapeutics Market Share by Country (2019-2030)

Figure 29. Germany Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. France Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. U.K. Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Italy Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Russia Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Nordic Countries Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Asia-Pacific Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Asia-Pacific Neuropathic Pain Therapeutics Market Share by Region (2019-2030)

Figure 37. China Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Japan Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. South Korea Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Southeast Asia Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. India Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Australia Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Latin America Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Latin America Neuropathic Pain Therapeutics Market Share by Country (2019-2030)

Figure 45. Mexico Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Brazil Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Middle East & Africa Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Middle East & Africa Neuropathic Pain Therapeutics Market Share by Country (2019-2030)

Figure 49. Turkey Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. Saudi Arabia Neuropathic Pain Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. Pfizer Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2019-2024)

Figure 52. Novartis AG Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2019-2024)

Figure 53. AstraZeneca Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2019-2024)

Figure 54. GlaxoSmithKline Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2019-2024)

Figure 55. Eli Lilly and Company Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2019-2024)

Figure 56. Mallinckrodt Pharmaceuticals Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2019-2024)

Figure 57. Johnson & Johnson Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2019-2024)

Figure 58. Abbott Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2019-2024)

Figure 59. Endo Pharmaceuticals, Inc. Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2019-2024)

Figure 60. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2019-2024)

Figure 61. Merck & Co Revenue Growth Rate in Neuropathic Pain Therapeutics Business (2019-2024)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions